Olivier Finaz

Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX.

Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The private company is based in St. Helier, UK.

Part of Pfizer Inc., Pfizer Group Ltd. is a British company that manufactures and sells pharmaceuticals, animal health products, and healthcare products. The private company is based in Sandwich, UK.

Part of Kirin Holdings Co., Ltd., OTL Pharma SA is a French company that develops and markets pharmaceutical products in the therapeutic areas of oncology, hematology, neurology, and supportive and intensive care. The private company is based in Paris, France. The company was founded by Marc Moguilewsky, Jean-François Labbé, Wim van Bree. OTL Pharma was acquired by Strakan Group Ltd. on January 26, 2004 for $8.92 million.

Founded in 1998, Kyowa Kirin Ltd. is a British pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Part of Kirin Holdings Co., Ltd., the private company is based in London, UK.

Covadis BV provides tailor-made software development services. The company is headquartered in Doetinchem, the Netherlands.

Centravet operates as a veterinary distribution center, which supplies medicine, food and material practitioners and to promote the veterinary surgeon. It offers TransNet, ivet, GmVet, Pilehairs, and Webveto solutions. The company was founded in 1972 and is headquartered in Taden, France.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.